Hostname: page-component-6766d58669-rxg44 Total loading time: 0 Render date: 2026-05-19T06:12:47.933Z Has data issue: false hasContentIssue false

Small cell neuroendocrine carcinoma of larynx: case series and literature review

Published online by Cambridge University Press:  15 July 2015

Muhammad Shahid Iqbal*
Affiliation:
Department of Clinical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcaslte upon Tyne, UK
V Paleri
Affiliation:
Department of Otolaryngology, Freeman Hospital, Newcastle upon Tyne, UK
J Moor
Affiliation:
Department of Otolaryngology, Sunderland Royal Hospital, UK
W Dobrowsky
Affiliation:
Department of Clinical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcaslte upon Tyne, UK
C Kelly
Affiliation:
Department of Clinical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcaslte upon Tyne, UK
J Kovarik
Affiliation:
Department of Clinical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcaslte upon Tyne, UK
*
Address for correspondence: Dr Muhammad Shahid Iqbal, Department of Clinical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK Fax: +44 191 2137691 E-mail: shahid.iqbal@nhs.net

Abstract

Background:

Primary small cell neuroendocrine carcinoma of larynx is a rare, aggressive type of malignancy. As only about 200 cases worldwide have been reported, any larger institutional experience is valuable. This study reports our experience in managing this rare entity.

Methods:

Of the nine patients identified, three had metastatic cancer at the time of diagnosis. Four patients underwent radical treatment: one was managed surgically followed by adjuvant chemotherapy and consolidation radiotherapy; the remaining three were treated with neoadjuvant chemotherapy and definitive radiotherapy.

Results:

Of the 4 patients treated with radical intent, 1 was alive and disease free after 99 months, 2 died of metastatic disease after 22 and 26 months, and 1 was alive after 20 months with a diagnosis of recurrent disease.

Conclusion:

Our relatively small number of patients confirms other centres' experiences. This cancer has a poorer prognosis than most other head and neck cancers. Although the logistics would be challenging, there is a need for international multicentre trials for this disease modelled on those performed for other cancers, as has been done for paediatric malignancies.

Information

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable